We are live on ! Find out more
MTNB icon

Matinas BioPharma

55 hedge funds and large institutions have $13.7M invested in Matinas BioPharma in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

2% more funds holding

Funds holding: 54 → 55 (+1)

0.25% less ownership

Funds ownership: 12.86% → 12.61% (-0.25%)

27% less capital inflows, than outflows

Capital inflows: $902K | Capital outflows: $1.24M

Holders
55
Holders Change
+1
Holders Change %
+1.85%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
10
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

MTNB Hedge Fund Activity: Q4 2022 in Review

55 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2022, worth a combined $13.7M — down 24% from $18M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new MTNB positions and 6 closed out — a net gain of 1 holder — while 10 added to existing stakes and 8 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $159K. The largest seller was BlackRock, cutting an estimated $1.04M.

  • 55 institutional investors held Matinas BioPharma (MTNB) as of Q4 2022, up from 54 in Q3 2022.
  • Funds reported $13.7M of Matinas BioPharma stock for Q4 2022, down 24% quarter-over-quarter.
  • 7 funds opened new Matinas BioPharma positions in Q4 2022 and 6 closed out, a net change of +1 holder.
  • The largest Matinas BioPharma buyer in Q4 2022 was Millennium Management, an estimated $159K added.
  • The largest Matinas BioPharma seller in Q4 2022 was BlackRock, an estimated $1.04M sold.

Based on aggregated 13F filings for Q4 2022.